Why Rare Disease Therapeutics Need Early Market Access Planning

When developing and bringing a therapeutic for a rare disease to market, sponsors should think with the end in mind and plan for payer requirements early in protocol design. The economic and clinical value evidence required by payers for market access differs from the clinical efficacy and safety evidence demanded by regulators. Securing approval but lacking market access results in unrealized revenue and, most importantly, patients left untreated. But how do we price and how do we gain access on the promise of long-term value when we don’t have the long-term data?

In this podcast, originally broadcast by The Conference Forum's PHARMA talkRADIO, Sangeeta Budhia, VP and Global Head, Pricing and Market Access, and Wyatt Gotbetter, Worldwide Head, Access Consulting, of Parexel discuss early market access planning, including inclusive data collection, payer models and the impact of new regulations and innovative trial design on data collection and ongoing evidence provision.

 

Return to Insights Center

Related Insights

Blog

Unpacking NICE’s review of the HST routing criteria: implications for manufacturers

Oct 3, 2024

Blog

Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024

Whitepaper

Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022

Webinar

China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?

Aug 17, 2022

Whitepaper

Addressing the Challenges of Artificial Intelligence used for Data Extraction in Systematic Literature Reviews

Mar 15, 2023

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Whitepaper

Reimbursement framework for medical devices in India

Mar 7, 2023

Playbook

Insights from the 2022 R&D Innovation Survey

Feb 17, 2023

Playbook

Are you using real-world evidence?

Feb 1, 2023

Blog

Innovative modeling method could speed patient access to critical IO therapies

Jan 4, 2023

Related Insights

Blog

Unpacking NICE’s review of the HST routing criteria: implications for manufacturers

Oct 3, 2024

Blog

Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024

Whitepaper

Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022

Webinar

China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?

Aug 17, 2022

Show more